Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

KDventures

0.14 SEK+7.73 %5/11 17:29
Less than 1K followers

KDV B

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+7.73 %
-46.74 %
-41.24 %
-46.74 %
-59.94 %
-79.69 %
-88.04 %
-95.14 %
-99.51 %

KDventures is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. KDventures was founded in 2003 and is headquartered in Solna, Sweden.

Read more
Market cap
107.94M SEK
Turnover
508.44K SEK
Revenue
1.67M
EBIT %
-11,617.24 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13/11
2026

Interim report Q3'26

12/2
2027

Annual report '26

29/4
2027

Interim report Q1'27

Regulatory press release2026-10-30 13:05

KDventures portföljbolag Umecrine Cognition rapporterar resultat från fas 1b/2a-studie med golexanolon vid PBC – innehavets redovisade värde justeras ned till noll

KDventures
Regulatory press release2026-10-30 13:05

KDventures portfolio company Umecrine Cognition reports results from Phase 1b/2a study of golexanolone in PBC – carrying value of holding to be adjusted to zero

KDventures
Regulatory press release2026-10-22 13:53

Finansinspektionen: Flaggningsmeddelande i KDventures AB

KDventures

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-10-21 16:00

KDventures portföljbolag Umecrine Cognition erhåller Notice of Allowance från USPTO för behandling av PBC-symtom med golexanolon

KDventures
Press release2026-10-21 16:00

KDventures portfolio company Umecrine Cognition receives Notice of Allowance from USPTO for treatment of PBC symptoms with golexanolone

KDventures
Press release2026-10-21 12:00

KDventures portföljbolag Modus Therapeutics SEVUSMART-studie publicerad i Nature Communications

KDventures
Press release2026-10-21 12:00

KDventures' portfolio company Modus Therapeutics' SEVUSMART study published in Nature Communications

KDventures
Press release2026-10-20 09:00

KDventures portföljbolag Umecrine Cognitions patientundersökning om extrem trötthet vid PBC utsedd till Poster of Distinction

KDventures
Press release2026-10-20 09:00

KDventures portfolio company Umecrine Cognition’s patient survey on severe fatigue in PBC selected as Poster of Distinction

KDventures
Regulatory press release2026-10-19 12:56

Finansinspektionen: Flaggningsmeddelande i KDventures AB

KDventures
Regulatory press release2026-10-15 17:00

John Öhd fokuserar på Modus Therapeutics och fortsätter som Senior Advisor till KDventures

KDventures
Regulatory press release2026-10-15 17:00

John Öhd focuses on Modus Therapeutics and continues as Senior Advisor to KDventures

KDventures
Press release2026-10-15 15:42

Redeye: KDventures: Safety Pause at Modus Delays Readout

KDventures
Press release2026-10-15 07:45

KDventures portföljbolag Modus Therapeutics pausar tillfälligt rekryteringen i fas 2a-studien med sevuparin vid kronisk njursjukdom med anemi

KDventures
Press release2026-10-15 07:45

KDventures portfolio company Modus Therapeutics temporarily pauses enrollment in Phase 2a study of sevuparin in chronic kidney disease with anemia

KDventures
Press release2026-10-07 13:00

KDventures portföljbolag Umecrine Cognition inbjudet att presentera Parkinsonprogram och nya translationella data vid The Michael J. Fox Foundations PDTC 2026

KDventures
Press release2026-10-07 13:00

KDventures portfolio company Umecrine Cognition invited to showcase Parkinson’s disease program and new translational data at The Michael J. Fox Foundation’s PDTC 2026

KDventures
Press release2026-09-30 12:34

Redeye: KDventures: Impressive but Dilutive Equity Issue for AnaCardio

KDventures
Press release2026-09-30 08:10

KDventures portföljbolag AnaCardio tar in 62,5 miljoner euro i Series B-finansiering

KDventures
Press release2026-09-30 08:10

KDventures’ portfolio company AnaCardio raises EUR 62.5 million in Series B financing

KDventures